News

Philips Advances Patient Care with Pioneering PAD Treatment

Philips Advances Patient Care with Pioneering PAD Treatment

Philips Leads the Way in Peripheral Artery Disease Treatment

Philips has recently achieved a remarkable milestone in the realm of healthcare with the enrollment of the first patient in a groundbreaking clinical trial in the United States. This innovative trial focuses on an integrated device that utilizes cutting-edge laser technology to treat peripheral artery disease (PAD), a condition that impacts millions globally.

Transforming Treatment with a Single Device

The innovative device developed by Royal Philips (NYSE: PHG, AEX: PHIA) combines two crucial PAD treatments: laser atherectomy and intravascular lithotripsy. Previously, managing PAD often required the use of multiple devices, leading to complex procedures. With this new integrated system, healthcare providers can now conduct necessary procedures more efficiently, potentially improving patient outcomes.

First Patient Treated in Innovative Trial

The Cardiovascular Institute of the South has successfully treated the trial's inaugural patient, a 78-year-old male suffering from peripheral vascular disease. This pivotal moment not only signifies the commencement of the THOR IDE clinical trial but also demonstrates the potential of the Philips laser catheter in simplifying the treatment workflow.

Importance of Clinical Evidence

As stated by Drs. Craig Walker and McCall Walker of the Cardiovascular Institute, creating robust clinical evidence is essential for enhancing patient care and promoting the adoption of new technologies. The THOR trial aims to gather comprehensive data to showcase how this innovative approach can optimize efficiency and patient outcomes, especially for those with challenging calcified lesions.

Addressing a Global Health Issue

PAD is a prevalent and severe condition that predominantly affects older adults and individuals with underlying health issues such as diabetes or high cholesterol. It leads to reduced blood flow, causing severe symptoms and potentially resulting in significant complications, including limb amputation.

The Philips Solution for PAD

The Philips laser catheter equips medical professionals with the necessary tools to address these challenges. By integrating both laser atherectomy and intravascular lithotripsy into a single device, healthcare providers are poised to simplify treatment, thus improving the patient experience. The laser-driven design of the catheter allows for simultaneous plaque removal and calcium disruption, providing a more streamlined approach to treatment.

Clinical Trial Overview

The THOR IDE trial is a prospective, single-arm, multicenter study anticipated to enroll up to 155 patients across 30 sites in the U.S. This study, facilitated under Investigational Device Exemption from the FDA, will rigorously evaluate the safety and effectiveness of the integrated device.

Evaluating Safety and Efficacy

Key endpoints of the clinical study encompass monitoring freedom from major adverse events within 30 days of the procedure, ensuring successful outcomes, and maintaining less than or equal to 50% residual stenosis post-treatment. Patients will be monitored over a year to track their progress and any complications that may arise.

Pioneering New Treatment Paradigms

Dr. Genovese, a vascular surgeon involved in the trial, expresses excitement about the innovative approach of combining atherectomy and intravascular lithotripsy. This methodology has the potential to significantly change how complex vascular challenges associated with calcifications are treated in patients.

Commitment to Innovation

Stacy Beske, Business Leader for Philips Image Guided Therapy Devices, emphasizes the company's dedication to developing advanced medical technologies. The combined laser atherectomy and intravascular lithotripsy device is a testament to Philips’ commitment to empower clinicians and transform the treatment landscape for PAD.

Currently, the Philips laser system remains investigational and is not available for commercial use. However, its potential to redefine treatment protocols for peripheral artery disease is on the horizon, showing promise for enhanced patient care.

Frequently Asked Questions

What is peripheral artery disease (PAD)?

PAD is a condition that reduces blood flow to the limbs, usually caused by atherosclerosis, leading to pain, ulcers, or even limb amputation.

How does the Philips integrated device work?

The device utilizes laser technology to perform both plaque removal and calcium disruption within a single procedure, streamlining the treatment process.

What are the goals of the THOR IDE trial?

The trial aims to assess the safety and effectiveness of the new laser device for treating complex, calcified lesions, with a primary focus on reducing complications.

Who can participate in the clinical trial?

The trial will enroll patients with peripheral artery disease, specifically those who face challenges due to calcified lesions.

Is the new Philips device currently available?

No, the device is currently investigational and is not yet available for commercial use.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 226

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 174

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 116

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 93

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 62

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 167

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 30

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 201

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

Balaji Srinivasan Links Bitcoin to Wealth and Health Preservation

Updated Category News Views 54

Balaji Srinivasan's Views on Bitcoin's Role Balaji Srinivasan, the former CTO of Coinbase, has been in the spotlight for his insights on how Bitcoin can help protect personal wealth. He draws a compelling comparison between Bitcoin and the pursuit of longevity in healthcare, suggesting both serve as defenses against state control over personal lives. Bitcoin as a Shield...

Continue Reading
Sequana Medical to Host Webinar on alfapump Commercial Launch

Updated Category News Views 213

Sequana Medical's Upcoming KOL Webinar on alfapump Launch Sequana Medical is set to host a Key Opinion Leader (KOL) webinar focused on the alfapump, designed for tackling recurrent and refractory ascites due to liver cirrhosis. This engaging session will take place on January 8. Experts from esteemed institutions will dive into vital discussions about the alfapump's...

Continue Reading
Qualcomm's Strategies to Navigate Competitive Market Pressures

Updated Category News Views 196

Qualcomm's Strong Market Position Despite Challenges Qualcomm Inc (NASDAQ: QCOM) has shown impressive resilience in the market, achieving significant growth largely due to its core chip business, which has seen double-digit growth. This is an encouraging sign of ongoing demand for its technology, particularly with high-end Android devices and innovations within artificial...

Continue Reading
Healthcare Providers Speak: A Study on Challenges and Care

Updated Category News Views 216

Healthcare Providers Speak: A Study on Challenges and Care Shapiro+Raj, a premier insights and strategy consultancy, has unveiled a significant study titled The Provider Perspective: Insights on Policy, Practice, and Patient Care. This comprehensive four-part series delves into the experiences of healthcare providers in the United States, highlighting their readiness to...

Continue Reading
PBOC Executes Groundbreaking Swap Operation of 50 Billion Yuan

Updated Category News Views 101

PBOC's Innovative Swap Operation The People's Bank of China (PBOC) has made waves in the financial sector by executing its very first swap operation involving a remarkable 50 billion yuan, equivalent to approximately 7.03 billion dollars. This pivotal event took place on a Monday, signifying a strategic move in China's monetary policy. Significance of the Swap Operation...

Continue Reading